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Abstract: Patients with iron deficiency anaemia are treated with oral iron supplementation, which is
known to cause gastrointestinal side effects by likely interacting with the gut microbiome. To better
study this impact on the microbiome, we investigated oral iron-driven changes in volatile organic
compounds (VOCs) in the faecal metabolome. Stool samples from patients with iron deficiency
anaemia were collected pre- and post-treatment (n = 45 and 32, respectively). Faecal headspace
gas analysis was performed by gas chromatography–mass spectrometry and the changes in VOCs
determined. We found that the abundance of short-chain fatty acids and esters fell, while aldehydes
increased, after treatment. These changes in pre- vs. post-iron VOCs resemble those reported when
the gut is inflamed. Our study shows that iron changes the intestinal metabolome, we suggest by
altering the structure of the gut microbial community.
Keywords: iron deficiency anaemia; iron supplementation; volatile organic compounds (VOCs);
intestinal metabolome; gut microbiome
1. Introduction
Iron is an essential element for numerous metabolic processes, including oxygen transport by
haemoglobin and myoglobin [1]. Iron deficiency anaemia (IDA) may arise from inadequate dietary
iron intake, malabsorption or blood loss, especially from the gastrointestinal tract [2].
Enteral iron absorption is tightly regulated. Its uptake is dependent on Divalent Metal-Transporter-1,
which allows the uptake of iron via the enterocytes in the enteral lumen [1,3]. Other key points are
the regulation of transferrin, which binds iron in the circulation; ferrireductases, which facilitate
absorption by converting iron from the insoluble ferric (Fe3+) form into the soluble ferrous (Fe2+)
state [1,3]; and hepcidin, an antimicrobial peptide that controls entry of iron into the plasma by binding
to and degrading ferroportin, an iron-exporting protein that is very highly expressed on the basolateral
membrane of enterocytes [1–3]. Under physiological conditions, these series of proteins ensure that
enough iron is absorbed, without leading to overload.
Oral iron supplements often exceed the absorptive capacity of the small intestine and the surplus
enters the colon where it can lead to gastrointestinal side effects [1,2,4,5] by the generation of free
radicals, which damage the epithelium [1,2], and by enhancing the growth of some, but not all,
enteric bacteria, leading to dysbiosis [6,7]. These adverse effects can be severe and contribute to the poor
compliance with iron therapy.
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Volatile organic compounds (VOCs) are carbon-based compounds with a high vapour pressure
(and low boiling point) that, consequently, readily enter the gaseous phase. They may contribute to
the odours that are associated with faeces and other bodily fluids. Faeces represent the end product
of enteric metabolism and digestion, and so changes in faecal VOCs can be used to study changes
in the intestinal metabolome and, by extension, the microbiome. Our aim was to explore oral iron-driven
changes in the enteral metabolome by comparing the VOC profiles of anaemic patients before and after
they had received oral iron supplementation.
2. Results
The samples were received as two groups (Table 1).
Table 1. Summary of age and sex of donors in the two groups.
Unpaired Samples, Group 1 Paired Samples, Group 2
Pre Post TotalSamples Pre Post
Total
Samples
Male:Female 21:14 8:14 57 4:6 4:6 20
Mean age (y) 71.4 71.1 69.5 NA
The median number of VOCs from Group 1 was 73.5 and 77 in the pre- and post-treatment
samples, respectively; for Group 2, the values were 68 and 71.5, respectively. Comparison of pre-
and post-treatment results in Group 1 found four VOCs that changed significantly in abundance:
two aldehydes increased (Table 2). Table 3 summarises the fold change in Group 1, in response to
the supplement.
Table 2. Volatiles that changed significantly after iron treatment in Group 1.
p False Discovery Rate Trend
Octanal 5.2 × 10−4 0.004 Increase
Heptanal 9.8 × 10−4 0.019 Increase
Ethyl hexanoate 4 × 10−4 0.015 Decrease
2,4-dimethylpentan-3-ol 9.5 × 10−4 0.019 Decrease
Table 3. Summary of fold change data in Group 1.
VOC That Decreased Fold Change VOC That Increased Fold Change
2,3,5-trimethylpyrazine 15.4 Octanal 7.3
Ethyl 2-phenylacetate 14.9 Heptanal 4.2
Ethyl hexanoate 13.3 2-pentylfuran 4.1
Methyldisulfanylmethane 12.0 Pentanal 3.1
Heptanoic acid 10.7 2-methyltetrazol-5-amine 2.8
4-methylpentanoic acid 8.4 Heptan-2-one 2.7
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Analysis of the 10 pairs of samples in Group 2 found no compounds that changed to a degree that
was statistically significant: this is likely to be a Type 1 error. We looked at the trend in fold change
in this cohort (Table 4). There were 27 VOCs that had a greater than two-fold difference between
the first and second sample: 6 compounds appeared more and 21 were less abundant; those that
increased included pentanal and 2-pentylfuran.
Table 4. Summary of fold change data in Group 2.
VOC That Decreased Fold Change VOC That Increased Fold Change
(1R,5S,6R,7S,10R)
4,10-dimethyl-7-propan-2-yltricyclo(4.4.0.0,5)dec-3-ene 20.1 2-pentylfuran 3.5
3-isopropenyl-1-isopropyl-4-methyl-4-vinylcyclohexene 14.0 methyldisulfanylmethane 3.4
ethyl butanoate 6.4 cyclohexanecarboxylicacid 2.9
butan-1-ol 6.4 hexanal 2.4
4-hydroxy-4-methylpentan-2-one 5.0 pentanal 2.3
















Heatmaps (Figure 1) were generated to illustrate the change in VOCs with treatment, for the two
groups. In the first, there is a clear cluster of nine VOCs that increased in abundance with treatment,
including four aldehydes (C5–C8), two secondary ketones (C4 and C7), 2-pentylfuran and octen-3-ol.
In the second, the six VOCs that increased included two aldehydes (C5 and C7), two secondary ketones
(C6 and C7) and 2-pentylfuran.
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Box and whisker plots were made to show the change in 2-pentylfuran and pentanal, as these
compounds were found to be significantly more abundant in Group 1 and to have greater than two-fold
change in abundance in both sets of data in response to treatment (Figure 2). The reduction in esters
in Group 1 was of interest as they suggested a change in the metabolism of this class of molecules
(Figure 3); however, this was not observed in Group 2.
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3. Discussion
We investigated the impact of oral iron replacement on the faecal metabolome in two groups of
patients. Patients in Group 1 provided unpaired samples of stool, which were taken before and after
iron therapy. Patients in Group 2 gave samples twice, enabling a paired analysis. The two groups
showed similar results with an increase in faecal aldehydes two months after starting treatment,
and there was a reduction in esters.
These changes were more evident, and statistically significant, in Group 1. However, there were
similar fold changes in both sets of data (Tables 3 and 4). Several VOCs, most notably aldehydes, had a
greater than two-fold increase in response to iron therapy in the follow-up samples (Tables 3 and 4).
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Aldehydes may be generated by lipid peroxidation in response to oxidative stress [8,9]. Inflammation
may also cause a change in this class [8]. This finding suggests that non-absorbed iron is damaging to
the epithelium; however, changes in the microbiome may be responsible for the increase.
Several ketones derived from secondary alcohols were also increased: such ketones may represent
oxidative stress but can be generated by the microbiome. The increase in heptan-2-one in the follow-up
samples is consistent with previously reported increases of 2-piperidone and 6-methylheptan-2-one
in patients with inflammatory bowel disease [8]. Heptan-2-one may play a part in inhibiting enteric
Escherichia coli [10].
There was an increase in oct-1-en-3-ol, which is strongly associated with fungi. Oct-1-en-3-ol was
found be in increased in patients with active Crohn’s disease [8]. 2-Pentylfuran is also synthesised by
fungi [11,12]. It is plausible that there is a change in the mycobiome in response to iron.
Heptanoic acid was markedly reduced in Group 1, following iron therapy. Recent in vitro models
have shown that medium chain fatty acids (MCFAs) are able to bind and form ligands with the gamma
class of peroxisome proliferator activated receptors (PPAR-γ). MCFAs are produced by intestinal
bacteria and may suppress colitis by activating PPAR-γ in macrophages [13].
The abundance of several short-chain fatty (SCFA) and other carboxylic acids was modestly reduced
in the follow-up samples. SCFAs are synthesised by bacterial fermentation of dietary fibre [14]. They are
important for intestinal health [14–16]. The reduction in SCFAs suggests that oral iron causes a reduction
in SCFA-producing bacteria. Lee et al. showed that oral iron may suppress Faecalibacterium prausnitzii
and Ruminococcus bromii [17]. Mahalhal et al. reported that iron supplements may suppress Firmicutes,
which are a major source of SCFAs [18].
Several fatty/carboxylic esters, including methyl pentanoate, ethyl hexanoate, butyl butanoate
and ethyl 2-phenylacetate (Figure 3), were decreased in post-iron samples. A decrease in esters was
previously reported in inflammatory bowel disease patients [8]. Faecal esters are likely to be derived
from the condensation of fatty acids and have been shown to aid the interactions between fatty acids
and gut epithelial cells [19]. A decline in both fatty acids and their esters may be a concomitant
process driven by the suppression of intestinal bacteria that produce fatty acids. This contrasts with
the increased enteric conversion of fatty acids into their esters, which would have been marked by
an increase in faecal esters and a decrease in fatty acids. It should be noted that this change was not
observed in the paired samples and it may be an artefact of the unpaired samples (Group 1) or a Type 1
error because Group 2 was smaller.
Esters may have an independent anti-inflammatory role in the gut. For example, oral treatment
with branched palmitic acid esters of hydroxy stearic acids has demonstrated a reduction in in vivo
colonic T cell activation and in expression of proinflammatory cytokines in mice, along with an in vitro
reduction in activation of dendritic cells and in the accompanying proliferation of T cells [20].
The patients who took part in the study all had differing underlying causes of IDA, although they
were referred to the clinic with suspected gastrointestinal cancer. Future studies in which the analysis
of patients is separated according to different IDA pathologies should be considered. Any ongoing
gastrointestinal blood lost would have increased liminal iron and reduced the changes observed in this
study. Future studies should look at patients taking iron for other indications (post-operatively or
in gynaecological clinics).
4. Materials and Methods
4.1. Patient and Stool Sample Selection
Patients with iron deficiency anaemia were recruited from a gastroenterology clinic before the cause
of the anaemia was diagnosed. Potential recruited patients gave written informed consent before study
procedures took place. Patients were treated with standard ferrous sulphate supplementation, up to
200 mg three times/day. Each participant provided two stool samples: the first before commencing iron
therapy and the second two months later. Ethical approval for the study was granted by the UK NHS
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Health Research Authority’s Research Ethics Service (RES) Committee South West—Central Bristol
(REC reference 14/SW/1162).
4.2. Extraction of VOCs
In order to perform metabolomic analysis, patients’ samples were sent to the University of
Liverpool, where they were stored in freezers at either −20 ◦C or −80 ◦C before being processed and run
through GC-MS (Perkin Elmer Clarus 500, Beaconsfield, UK) apparatus.
With extensive expert technical assistance in the laboratory, all faecal samples were analysed
by way of a quadruple GC-MS benchtop system that was used in conjunction with a CombiPAL
autosampler (CTC Analytics, Zwingen, Switzerland). The carrier gas used was helium at a very high
purity (BOC, Sheffield, UK).
A local laboratory protocol was followed, which was based on the standardised recommendations
of GC-MS method optimisation that were proposed by Reade et al. [21]. Every effort was taken
to aliquot at least 500 mg of each faecal sample into a vial that had a magnetic cap and a volume
of 10 mL. Although this was not possible for every sample, as some samples had limited faecal
quantity, all aliquots had a minimum range of 50–100 mg, which was deemed to be sufficient for
GC-MS analysis [21]. Thereafter, the samples were incubated at 60 ◦C for 30 min. Extraction of VOCs
from the vial headspace was itself achieved by utilising solvent-free solid phase micro-extraction
(SPME) fibres of the CAR-PDMS 85 µm variety (Sigma-Aldrich, Dorset, UK), which were appropriately
pre-conditioned prior to use.
4.3. Downstream Data Processing and Analysis
After thorough evaluation of each chromatogram produced by the GC-MS, additional data
inspection and processing were carried out using the Automated Mass Spectral Deconvolution
and Identification System (AMDIS version 2.70, https://amdis.software.informer.com/2.7/) software.
This was used in tandem with the US National Institute of Standards and Technology’s (NIST) Mass
Spectral Library (version 2.71, (https://www.perkinelmer.com/uk/product/nist-2011-mass-spectral-
library-and-software-n6520220)). By manually analysing chromatograms and mass spectra on AMDIS
of over 40 of the first samples that were run on the GC-MS, a project-specific library of compounds was
created using the NIST database. In addition to taking into account the highest percentage compound
match with NIST spectra, VOCs were only included in the library if they had been identified with a
minimum match factor of 800.
At this stage, because these samples were blinded, the library was built by incorporating the VOCs
found in both pre-iron and post-iron patients. This library eventually comprised over 300 VOCs,
which were all named as per the nomenclature standards set by the International Union of Pure
and Applied Chemistry (IUPAC) [22]. Once the library was saturated, the iron status (i.e., pre- or post-)
of each sample was categorised, and all the samples were collectively analysed together using AMDIS’s
batch report function. These data were then further processed and corrected for downstream analysis
by using the Metab script package [23], which was utilised within the R (version 3.5, 2018) program.
Subsequently, all statistical analyses were carried out using MetaboAnalyst, a widely used
online tool devoted to metabolomic analysis [24]. The principal settings that were utilised included
the removal of over 70% of missing metabolite values, though data filtering was not applied. Data
were, however, normalised by the median and log-transformed, in addition to being auto-scaled;
i.e., mean-centring and then division by the standard deviation of each variable took place. In terms of
univariate analysis, fold change analysis and t-tests were carried out, with statistical significance being
set at a p-value less than 0.05. Multivariate analysis centred on principal component analysis (PCA)
and partial least squares–discriminant analysis (PLS-DA).
Crucially, in terms of the experimental procedure, VOC extraction was carried out in two batches.
Group 1 comprised 35 pre- and 22 post-iron samples that were all from different patients, whereas
Group 2 had 10 pre- and 10 post-iron samples each that were all from the same patients (i.e., they were
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paired samples). Thus, 57 samples were analysed in the first run and a total of 20 samples in the second
validation run.
5. Conclusions
This study has shown that oral iron replacement is associated with changes in the faecal
metabolome. There is an increase in aldehydes, which may be a result of oxidative stress, and a
reduction in esters that may reflect an alteration in the microbiome.
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